Fig 1: Functional characterization of PSME2 in ccRCC using WGCNA and GSEA. (A) WGCNA hierarchical cluster dendrogram of the top 25% genes ranked by SD from large to small ccRCC. Each branch in the tree represents one gene. Each color represents one co-expression module. (B) PCC matrix of the correlation between MEs and clinicopathological status (normal and tumor) of ccRCC. Each row corresponds to a colored ME detected using WGCNA, and each column corresponds to a trait. The values of PCC ranged from -1 to 1 depending on the strength of the relationship. A positive value means that the probe sets in a specific co-expression module increase as the variable increases, while a negative value indicates a specific co-expression module decreases as the variable decreases. Each PCC value has the corresponding P-value in brackets. (C) GO enrichment analysis using The Database for Annotation, Visualization and Integrated Discovery. The horizontal axis represents the proportion of PSME2 enriched in each GO term. The vertical axis represents the annotation terms. The size of the bubble represents the number of genes in each GO term; depth of each circle color represents P-value. (D) KEGG enrichment for the differentially expressed genes in Fig. 3B. (E) GSEA revealing cytokine-cytokine receptor interaction and TNF signaling pathway associations between tumor and normal samples from TCGA. (F) GSEA revealing autophagy-animal, cytokine-cytokine receptor interaction and NF-κB signaling pathway associated with PSME2 expression levels from TCGA database. ME, module eigengenes; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; WGCNA, weighted gene co-expression network analysis; GSEA, Gene Set Enrichment Analysis; TCGA, The Cancer Genome Atlas; PSME2, proteasome activator complex subunit 2; ccRCC, clear cell renal cell carcinoma; NES, normalized enrichment score; FDR, false discovery rate; PCC, Pearson's correlation coefficient.
Fig 2: Effects of BNIP3 overexpression on autophagy and tumor cytokine expression level with or without siPSME2 in the CAKI-1 cell line. (A) Western blot analysis of autophagy-related proteins and PSME2 in empty vector and BNIP3-overexpressing cells at 12, 24 and 48 h following transfection, and the results were quantified using densitometry. *P<0.05, **P<0.01, compared to vector. (B) IL-6, TNF-α, CXCL9, CXCL10 and BLys mRNA expression levels were measured using reverse transcription-quantitative PCR. The cells were transfected with either empty plasmid or BNIP-3 overexpression vector for 24 and 48 h. (C) Subcellular localizations of LC3 were determined using confocal microscopy. Scale bar, 10 µm. (D) Transmission electron microscope of the CAKI-1 cell line transfected with empty plasmid or BNIP-3 overexpression vector for 24 and 48 h. Top scale bar, 5 µm; bottom scale bar, 1 µm. (E) Invasion of the CAKI-1 cell line simultaneously transfected with siBNIP3 and siPSME2 using a Transwell invasion assay. Scale bar, 200 µm. (F) A total of five protein biomarkers were found to be differentially expressed in BNIP3 or/and PSME2 knockout cells and the results were quantified using densitometry. PSME2, proteasome activator complex subunit 2; si, small inhibiting; NC, negative control; SQSTM1, sequestersome 1; BNIP3, BCL2 interacting protein; CXCL, C-X-C motif chemokine ligand; BLys, B lymphocyte stimulator.
Fig 3: Expression levels of PSME2 in renal tumors, adjacent normal tissues, and renal cancer and normal cell lines. (A) Iummohistochemistry expression levels of PSME2 in cancer and adjacent normal tissues. Scale bar, 100 µm. Western blot analysis of PSME2 expression levels in (B) cancer and adjacent normal tissues, and (C) HK-2,786-O, CAKI-1, ACHN and A498 cell lines. PSME2, proteasome activator complex subunit 2. **P<0.01. ***P<0.001.
Fig 4: Expression profiling of PSME2 in diverse types of cancer and association of PSME2 expression with prognosis. (A) The PSME2 gene expression level in different types of cancer and normal tissues using the Oncomine database. The graph represents the datasets with statistically significant (P<0.01) overexpression (red) or lower expression (blue) in PSME2. (B) PSME2 differential expression level in 33 types of cancer (n=486) and normal (n=338) tissues from The Cancer Genome Atlas database. *P<0.05, **P<0.01, ***P<0.001. PSME2 gene expression was associated with (C) OS, (D) DSS and (E) PFS time Kaplan-Meier survival analysis. HR, hazard ratio; OS, overall survival; DSS, disease-free survival; PFS, progression-free survival; ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, brain lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma; PSME2, proteasome activator complex subunit 2.
Fig 5: Effects of PSME2-knockdown on autophagy and tumor cytokine expression in the CAKI-1 and 786-O cell lines. (A) Autophagy-associated proteins were detected using western blot analysis and the results were quantified using densitometry. The data are presented as the mean ± SD from three independent experiments. *P<0.05, **P<0.01. (B) The mRNA expression level of IL-6, TNF-α, CXCL9, CXCL10 and BLys were determined in the CAKI-1 and 786-O cell lines using reverse transcription-quantitative PCR. *P<0.05, **P<0.01, compared to siNC control. (C) Cell invasion of CAKI-1 and 786-O cell lines transfected with siPSME2 or siNC were analyzed following treatment with Baf-A1. Scale bar, 200 µm. (D) Transmission electron microscopy of autophagosomes in renal carcinoma cells transfected with siRNAs. Left scale bar, 5 µm; right scale bar, 1 µm. PSME2, proteasome activator complex subunit 2; si, small inhibiting; NC, negative control; Baf-A1, bafilomycin A1; SQSTM1, sequestersome 1; BNIP3, BCL2 interacting protein; CXCL, C-X-C motif chemokine ligand; BLys, B lymphocyte stimulator.
Supplier Page from Abcam for Anti-PSME2 antibody [EPR14931]